PATENT CLAIM ANALYSIS

Application Number: 15867655
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "019300"]

Abstract:
The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein alone or in combination with IL-2 and/or an immune stimulant (i.e., an immune checkpoint stimulator), and/or an immune checkpoint inhibitor. The invention also provides composition for use in such methods.

Claim (Index 32):
An expression vector comprising a nucleic acid encoding an integrin-binding polypeptide-Fc fusion as described herein.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 86.0
- Lexical Diversity: 1.38889
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15608715', '15501028', '14755989', '15636711', '15399122']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8249423725080981
- 35 USC 102 Novelty (BERT): 0.6085039140456111
- Combined Prediction Score: 0.8032985266618493
- Mean Citation Score: 463.42347800000016
- Max Citation Score: 663.7533
- Similarity Product: 462.8851946476758

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test